Pharmaceutical - Biogen Idec

Filter

Current filters:

Biogen Idec

Popular Filters

1 to 25 of 53 results

FDA adds warning to Tecfidera label after patient death

FDA adds warning to Tecfidera label after patient death

26-11-2014

The US Food and Drug Administration has issued a warning that a patient with multiple sclerosis who was…

Biogen IdecCNS DiseasesPharmaceuticalRegulationTecfideraUSA

Sobi pays $10 million to exercise opt-in right for Elocta

Sobi pays $10 million to exercise opt-in right for Elocta

21-11-2014

Nordic biotech firm Swedish Orphan Biovitrum will exercise its opt-in right to take over final development…

Biogen IdecElocateEloctaFinancialHematologyPharmaceuticalSobiSweden

Despite patent cliffs, pharma market shows signs of stability

19-11-2014

The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies…

Biogen IdecBoehringer IngelheimFinancialJohnson & JohnsonPatentsPfizerPharmaceutical

Highlights of EMA Pharmacovigilance unit meeting

09-11-2014

At its meeting last week, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee…

BayerBiogen IdecCSL BehringEuropeHelixateHematologyKogenateNeurologicalPharmaceuticalRegulationTecfidera

Major step forward for multiple sclerosis treatment in New Zealand

13-10-2014

Funding for newer and more effective multiple sclerosis (MS) treatments has been approved by PHARMAC,…

Biogen IdecCopaxoneFinancialGilenyaHealthcareNeurologicalNew ZealandNovartisPharmaceuticalTeva Pharmaceutcal IndustriesTysabri

Biogen and AbbVie report reduced disease activity with MS drug Zinbryta

Biogen and AbbVie report reduced disease activity with MS drug Zinbryta

18-09-2014

US biotech company Biogen Idec and US pharma giant AbbVie have announced the full results from the Phase…

AbbVieAvonexBiogen IdecImmune systemMultiple sclerosisNeurologicalPharmaceuticalResearchUSAZinbryta

Multiple sclerosis treatments funding proposal in New Zealand

Multiple sclerosis treatments funding proposal in New Zealand

07-08-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a funding proposal involving…

Biogen IdecFinancialGilenyaNeurologicalNew ZealandNovartisPharmaceuticalTysabri

Biogen Idec’s Plegridy approved in Europe for relapsing-remitting multiple sclerosis

Biogen Idec’s Plegridy approved in Europe for relapsing-remitting multiple sclerosis

24-07-2014

US biotech firm Biogen Idec said that the European Commission has approved its subcutaneous injectable…

Biogen IdecCytokinesMultiple sclerosisNeurologicalPharmaceuticalPlegridyRegulationUSA

Biogen and AbbVie release Phase III data for MS treatment

Biogen and AbbVie release Phase III data for MS treatment

17-06-2014

US biotech firm Biogen Idec and US drugmaker AbbVie have announced positive top-line results from the…

AbbVieBiogen IdecCNS DiseasesdaclizumabPharmaceuticalResearchUSA

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

Eisai expands deal with Biogen; re-files Fycompa with G-BA; news on Zebinix

12-05-2014

Japanese drug major Eisai has exercised its option to jointly develop and commercialize its clinical…

Biogen IdecEisaiFycompaGermanyItalyLicensingNeurologicalPharmaceuticalPricingRegulationZebinix

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

European neurologists expect Biogen Idec’s Tecfidera to be preferred MS drug

16-04-2014

Surveyed neurologists in France, Germany, Italy, Spain and the UK project that 16% of their diagnosed…

AubagioBiogen IdecChemistryCNS DiseasesEuropeGenzymeMajorPharmaceuticalPharmacologyPhysicianResearchSANTecfidera

Health Canada approves Biogen Idec’s long-acting Alprolix hemophilia B

Health Canada approves Biogen Idec’s long-acting Alprolix hemophilia B

21-03-2014

US biotech firm Biogen Idec has announced that Health Canada has approved Alprolix for the control and…

AlprolixBiogen IdecCanadaHematologyPharmaceuticalRegulation

William Young to retire from Biogen’s board of directors after 17 years

William Young to retire from Biogen’s board of directors after 17 years

17-02-2014

US biotech firm Biogen Idec has announced today that chairman of the board William Young, known as Bill,…

Biogen IdecBoardroomPharmaceuticalUSA

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

Royalty Pharma acquires additional interest in Tecfidera for $510 million

Royalty Pharma acquires additional interest in Tecfidera for $510 million

06-01-2014

US private equity firm Royalty Pharma says that it has acquired an additional interest in the earn-out…

Biogen IdecDermatologicalsFumadermFumapharmLicensingNeurologicalPharmaceuticalRoyalty PharmaTecfidera

ASH 2013: Meeting highlights from Novartis, Takeda, Biogen Idec and SOBI

ASH 2013: Meeting highlights from Novartis, Takeda, Biogen Idec and SOBI

10-12-2013

This year’s American Society of Hematology (ASH) meeting continued yesterday with more clinical trial…

Biogen IdecEloctateHematologyJakaviNovartisPharmaceuticalResearchSobiTakeda PharmaceuticalsUSA

2013 FDA approval rates suggest record year for post-launch success

14-11-2013

A focus on hard to treat or specialist diseases is set to result in record post-launch sales for new…

Biogen IdecFinancialGilead SciencesNorth AmericaPharmaceuticalRegulationsofosbuvirTecfidera

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

26-09-2013

The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

Mixed US views on Gilenya, Aubagio and Tecfidera as breakthrough MS drugs

03-09-2013

More than half of surveyed neurologists consider US biotech firm Biogen Idec's (Nasdaq: BIIB) Tecfidera…

AubagioBiogen IdecGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalPricingSanofiTecfidera

Multiple sclerosis market could reach $18.3 billion in 2018

19-08-2013

The multiple sclerosis (MS) market is expected to peak at $18.3 billion in 2018, according to healthcare…

AubagioBiogen IdecFinancialGilenyaGlobalNovartisPharmaceuticalSanofiTecfidera

EU5 rheumatologits rate Rituxan and Benlysta for Lupus

12-08-2013

Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Biogen Idec's marketing applications for MS drug Plegridy accepted for review in USA and EU

19-07-2013

US biotech firm Biogen Idec (Nasdaq: BIIB) says that its marketing applications for Plegridy (peginterferon…

Biogen IdecEuropeMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPlegridy

1 to 25 of 53 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top